IRIS
GIULIANI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.555
AS - Asia 14.234
EU - Europa 8.879
SA - Sud America 1.830
AF - Africa 803
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 7
Totale 40.330
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.110
SG - Singapore 5.240
CN - Cina 4.110
VN - Vietnam 2.235
IE - Irlanda 1.616
SE - Svezia 1.517
BR - Brasile 1.430
FI - Finlandia 1.133
HK - Hong Kong 993
IT - Italia 967
DE - Germania 954
UA - Ucraina 647
FR - Francia 563
ZA - Sudafrica 537
TR - Turchia 524
NL - Olanda 414
GB - Regno Unito 297
CA - Canada 289
IN - India 232
RU - Federazione Russa 182
AR - Argentina 157
BD - Bangladesh 155
AT - Austria 121
JP - Giappone 93
CI - Costa d'Avorio 90
MX - Messico 90
IQ - Iraq 82
KR - Corea 72
RO - Romania 69
BE - Belgio 65
ES - Italia 65
PL - Polonia 65
CZ - Repubblica Ceca 58
EC - Ecuador 58
PH - Filippine 58
PK - Pakistan 56
TH - Thailandia 53
ID - Indonesia 44
CO - Colombia 43
VE - Venezuela 41
UZ - Uzbekistan 39
MA - Marocco 37
LT - Lituania 35
PY - Paraguay 27
CL - Cile 24
TW - Taiwan 24
AE - Emirati Arabi Uniti 23
SA - Arabia Saudita 23
EG - Egitto 22
KE - Kenya 21
IR - Iran 20
UY - Uruguay 20
EU - Europa 18
JO - Giordania 18
MY - Malesia 18
PE - Perù 18
ET - Etiopia 17
TN - Tunisia 17
IL - Israele 16
KZ - Kazakistan 15
BG - Bulgaria 14
CR - Costa Rica 14
AL - Albania 13
BO - Bolivia 12
JM - Giamaica 11
NP - Nepal 11
CH - Svizzera 10
DZ - Algeria 9
OM - Oman 9
SN - Senegal 9
DO - Repubblica Dominicana 8
HU - Ungheria 8
LV - Lettonia 8
PT - Portogallo 8
QA - Qatar 8
LB - Libano 7
NG - Nigeria 7
PA - Panama 7
AM - Armenia 6
AZ - Azerbaigian 6
MD - Moldavia 6
PS - Palestinian Territory 6
DK - Danimarca 5
GA - Gabon 5
HN - Honduras 5
RS - Serbia 5
SY - Repubblica araba siriana 5
TT - Trinidad e Tobago 5
AO - Angola 4
AU - Australia 4
BW - Botswana 4
BY - Bielorussia 4
EE - Estonia 4
GR - Grecia 4
HR - Croazia 4
KG - Kirghizistan 4
KH - Cambogia 4
KW - Kuwait 4
LU - Lussemburgo 4
NI - Nicaragua 4
Totale 40.252
Salva come PNG Salva come JPEG
Città #
Singapore 2.620
Ashburn 1.747
Chandler 1.637
Dublin 1.608
San Jose 1.259
Beijing 1.012
Hong Kong 932
Santa Clara 882
Dallas 842
Jacksonville 762
Ho Chi Minh City 666
Hanoi 516
Johannesburg 509
Boardman 496
Nanjing 410
Izmir 405
Parma 385
Dearborn 382
Ann Arbor 346
Los Angeles 340
Princeton 322
Shanghai 320
Lauterbourg 316
New York 270
San Mateo 233
Munich 214
Wilmington 186
Toronto 166
Shenyang 159
Hefei 156
Kunming 147
Marseille 140
São Paulo 138
Nanchang 137
Helsinki 135
Düsseldorf 125
Buffalo 111
Jinan 106
Columbus 105
Hebei 105
Vienna 99
Moscow 97
Da Nang 95
Abidjan 90
Haiphong 90
Des Moines 87
Tianjin 86
Jiaxing 78
Turku 78
The Dalles 76
Bremen 74
Council Bluffs 73
Tokyo 72
Seattle 70
Changsha 66
Brussels 64
Orem 60
Warsaw 56
Montreal 54
Woodbridge 54
Kocaeli 52
Milan 51
Guangzhou 50
Seoul 49
Frankfurt am Main 47
Houston 47
Pune 46
Rio de Janeiro 46
Hangzhou 45
London 45
Atlanta 43
Brooklyn 43
Phoenix 43
Hải Dương 41
Nuremberg 41
Poplar 40
Stockholm 40
Amsterdam 39
Focsani 39
Brno 37
Chicago 37
Norwalk 37
Biên Hòa 36
Tashkent 35
Zhengzhou 35
Bologna 34
Can Tho 34
Denver 34
Chennai 33
Boston 29
Grafing 29
San Francisco 28
Ankara 27
Rome 27
Dhaka 26
Belo Horizonte 25
Baghdad 24
Manchester 24
Redondo Beach 24
Brasília 23
Totale 24.351
Salva come PNG Salva come JPEG
Nome #
Are the Myeloma bone microevironment cells tumoral or not? 222
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 216
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 212
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 210
Angiopoietin-1 and Osteopontin Expression by CD138+ Myeloma Cells Rather Than VEGF and CD45 Correlates with Bone Marrow Angiogenesis in Multiple Myeloma Patients at the Diagnosis 209
A simplified sars-cov-2 pseudovirus neutralization assay 208
(2S,4R)-4-fluoroglutamine is converted into (2S,4R)-4-fluoroglutamate by glutaminase activity and may be exploited as a PET tracer in glutamine-addicted cancers 205
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 203
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma 198
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 195
Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo 190
The Proteasome and Myeloma-Associated Bone Disease 189
Novel targets for the treatment of relapsing multiple myeloma 189
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 189
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 187
A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis 186
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 184
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 182
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 182
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 180
Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML 180
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 179
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 178
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 178
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia 177
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 177
The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment 176
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 175
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 172
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 172
Chemokine receptors CXCR3 and CXCR4 expression in B cell and plasma cell malignancy 170
5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men. 170
Angiopoietin-1 and osteopontin expression by CD138+myeloma cells rather than VEGF and CD45 correlates with bone marrow angiogenesis in Multiple Myeloma patients at the diagnosis. 169
Bisphosphonates inhibit IL-6 production by human osteoblast-like cells 168
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 167
Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients 167
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 166
ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION 165
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 164
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma 162
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 161
Functional consequences of low activity of transport system a for neutral amino acids in human bone marrow mesenchymal stem cells 161
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 158
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 158
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 157
Concomitant primary hyperparathyroidism in patients with multiple myeloma: A possible link? 157
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 156
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome 156
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 156
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 156
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 155
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 155
A translocation t(4;13)(q21;q14) as single clonal chromosomal abnormality in a parathyroid adenoma 155
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 155
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 155
Angiopoietins expression by human myeloma cells 154
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 154
GPNA inhibits the sodium-independent transport system l for neutral amino acids 153
Amlexanox inhibition of TBK1/IKK epsilon Signaling Is a Novel Therapeutic Approach for Multiple Myeloma-Induced Bone Disease. 153
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 153
Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL 152
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients 151
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 151
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 150
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 150
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 150
Angiogenic switch in multiple myeloma patients 149
Autologous bone marrow transplantation in acute myeloid leukemia: a single center experience 149
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage 148
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. 147
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 147
Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma 147
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 147
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 147
Angiogenic properties of human myeloma cells: role of angiopoietin system 146
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 146
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 146
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy 146
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 145
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 145
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 144
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 144
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 144
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. 144
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 144
Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking 143
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 143
Angiogenesis and multiple myeloma 142
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 141
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 140
Analysis of lineage involvment in Philadelphia chromosome positive acute lymphoblastic leukaemia 140
Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients 140
Ectopic production of osteopontin by human myeloma cells and its involvement in myeloma induced angiogenesis 140
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 139
Do human myeloma cells directly produce basic FGF? 139
Alterations of microenvironment in multiple myeloma patients: Interactions between myeloma cells and osteoprogenitor cells 139
The osteoblastic niche in the context of multiple myeloma 138
Arginine Vasopressin and Oxytocin responses to angiotensin II are mediated by AT1 receptor subtype in normal men 138
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 138
Angiopoietin-1 and myeloma-induced angiogenesis 137
Totale 16.262
Salva come PNG Salva come JPEG
Categoria #
all - tutte 137.694
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.694
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021446 0 0 0 0 0 0 0 0 0 87 292 67
2021/20221.588 31 23 26 110 37 57 199 202 77 145 128 553
2022/20236.236 723 644 385 451 531 669 158 398 1.953 74 185 65
2023/20242.278 110 237 55 57 190 623 194 163 54 125 152 318
2024/20257.370 117 402 434 583 797 686 288 319 978 668 632 1.466
2025/202615.371 1.425 1.465 2.034 1.513 2.345 953 1.717 601 2.150 1.168 0 0
Totale 40.786